Phaseline

Targets › GPRC5D

GPRC5D (G protein-coupled receptor family C group 5 member D): drug programs, companies and trials

15 programs from 13 companies in 66 trials: 29 Phase 1, 27 Phase 2, 9 Phase 3, 1 Phase 4; Oncology, Other, Immunology; next expected readout Nov 2026.

G protein-coupled receptor involved in hard keratin expression and likely plays a role in the development of hair and nails. (UniProt, Q9NZD1)

Open in Phaseline: the race on GPRC5D, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Regeneron PharmaceuticalsLinvoseltamab
anti-B-cell maturation antigen x anti-CD3 bispecific antibody
BCMA, GPRC5D, CD3E, TNFRSF17Phase 4Relapsed/Refractory Multiple Myeloma (RRMM); Relapsed and/or Refractory Multiple Myeloma (RRMM); Relapsed Refractory Multiple Myeloma (RRMM); High Risk Smoldering Multiple Myeloma (HR-SMM) …Aug 2027
Johnson & Johnson (Janssen)Talquetamab
T cell surface glycoprotein CD3 binding agent; G-protein coupled receptor family C group 5 member D binding agent
CD3E, CD3G, CD3D, GPRC5DPhase 3Multiple Myeloma; Hematological Malignancies; Relapsed/ Refractory Multiple Myeloma; Multiple Myeloma (MM) …Apr 2027
Johnson & Johnson (Janssen)Ramantamig
BCMAxGPRC5DxCD3 trispecific antibody
TNFRSF17, CD3E, BCMA, GPRC5DPhase 3Multiple MyelomaDec 2027
Institute of Hematology & Blood Diseases Hospital, ChinaGPRC5D/CD3 BiTEs
Bispecific T-cell engager targeting GPRC5D and CD3
GPRC5D, CD3EPhase 2Multiple Myeloma, Newly Diagnosed; Multiple Myeloma, Plasma Cell LeukemiaAug 2027
Institute of Hematology & Blood Diseases Hospital, ChinaQLS4131
BCMA/GPRC5D/CD3 trispecific antibody
BCMA, GPRC5D, CD3Phase 2Primary Plasma Cell LeukemiaDec 2029
OriCell TherapeuticsOriCAR-017
GPRC5D-directed chimeric antigen receptor (CAR) modified T cells
GPRC5DPhase 1Relapsed and/or Refractory Multiple Myeloma; Neoplasms, Plasma CellNov 2026
Beijing GoBroad HospitalDual-targeting BCMA-GPRC5D CAR-T cell
Dual-target CAR-T cell therapy targeting BCMA and GPRC5D
BCMA, GPRC5DPhase 1Relapsed or Refractory Multiple Myeloma (RRMM)May 2027
Peking University First HospitalGPRC5D-targeted radiotracer
GPRC5D-targeted PET radiotracer
GPRC5DPhase 1Plasma Cell DisordersMay 2027
BayerActinium-225-macropa-pelgifatamab (BAY3546828)
Alpha-emitting radiopharmaceutical targeting GPRC5D; actinium-225 chelated by macropa conj
GPRC5DPhase 1Metastatic Castration-resistant Prostate CancerJun 2027
Essen BiotechBCMA/GPRC5D CAR-T cells
Chimeric Antigen Receptor T cells targeting BCMA and/or GPRC5D
BCMA, GPRC5DPhase 1Multiple MyelomaDec 2027
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin PharmaceuticalTQB2029 for injection
bispecific antibody targeting GPRC5D and CD3; recruits and activates CD3+ T cells to kill
GPRC5D, CD3Phase 1Multiple MyelomaMar 2028
O&D BioTech GroupO&D-001 injection
Chimeric antigen receptor T cell targeting BCMA and GPRC5D
BCMA, GPRC5DPhase 1Relapsed or Refractory Multiple MyelomaMar 2028
Bristol-Myers SquibbAlnuctamab (BMS-986349, CC-93269, EM901)
GPRC5D-targeting monoclonal antibody
GPRC5DPhase 1Multiple Myeloma; Systemic Lupus ErythematosusAug 2028
Chunrui LiCAR-GPRC5D
CAR-T cell therapy targeting GPRC5D
GPRC5DPhase 1Relapsed/Refractory Multiple Myeloma–
Nanjing IASO BiotechnologyCAR-GPRC5D (RD118)
anti-GPRC5D CAR-T cell therapy
GPRC5DPhase 1Relapsed/Refractory Multiple Myeloma–

Conditions

Multiple Myeloma (32) Relapsed Refractory Multiple Myeloma (RRMM) (3) Relapsed/Refractory Multiple Myeloma (3) Multiple Myeloma, Newly Diagnosed (2) Hematological Malignancies (2) Multiple Myeloma (MM) (2) Relapsed/Refractory Multiple Myeloma (RRMM) (1) Relapsed and/or Refractory Multiple Myeloma (RRMM) (1) High Risk Smoldering Multiple Myeloma (HR-SMM) (1) Monoclonal Gammopathy of Undetermined Significance (MGUS) (1) Smoldering Multiple Myeloma (SMM) (1) Food Allergy (1)

Modalities

mixed (5), other (4), small molecule (3), antibody (1), protein or peptide (1)

Companies

Johnson & Johnson (Janssen) (2) Institute of Hematology & Blood Diseases Hospital, China (2) Regeneron Pharmaceuticals (1) Bristol-Myers Squibb (1) Nanjing IASO Biotechnology (1) Beijing GoBroad Hospital (1) O&D BioTech Group (1) Essen Biotech (1) OriCell Therapeutics (1) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical (1) Bayer (1) Chunrui Li (1) Peking University First Hospital (1)

Related targets

BCMA (6) CD3E (4) TNFRSF17 (2) CD3 (2) CD3G (1) CD3D (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.